Taw qhia:
EXenatide acetate hmoov derivation, ib daim ntawv tshuaj uas muaj qhov chaw nrog chav kawm ntawm glucagon-zoo li peptide -1 receptor agonists (GLP-1 RAs), tau tshwm sim los ua ib qho kev xaiv tseem ceeb hauv kev tswj hwm hom 2 mob ntshav qab zib mellitus. Nws multifaceted mechanism ntawm kev txiav txim thiab array ntawm cov txiaj ntsig ua rau nws lub hauv paus pob zeb hauv armamentarium tawm tsam qhov teeb meem metabolic.
Ib qho ntawm cov cuab yeej tseem ceeb uas dhau los ntawm exenatide acetate derivation siv nws cov kev cuam tshuam rov qab yog los ntawm kev tsom mus rau kev ua haujlwm ntawm endogenous glucagon-zoo li peptide-1 (GLP-1). GLP-1 yog ib qho tshuaj incretin uas tso tawm los ntawm lub plab zom mov vim kev noj tshuaj ntxiv, ua kom cov tshuaj insulin tawm los ntawm pancreatic beta hlwb hauv txoj kev qabzib. Tsis tas li ntawd, GLP -1 smothers glucagon tawm, eases rov qab gastric purging, thiab nce satiety, tag nrho cov ntxiv rau txhim kho glycemic tswj.
Los ntawm kev ua kom GLP-1 receptors,exenatide acetate hmoovamplifates cov txiaj ntsig zoo no.Nws txhim kho cov piam thaj-sab hauv insulin tso tawm, raws li cov kab no ua rau txo qis cov ntshav qabzib tom qab thiab yoo mov. Tsis tas li ntawd, nws cov haujlwm inhibitory ntawm glucagon emission pab nrog kev cuam tshuam txog kev tsim cov piam thaj hauv siab, txhawb ntxiv kev tswj glycemic. Lub deceleration ntawm gastric discharging rub tawm cov assimilation ntxiv, ua rau cov qib qabzib ntau dua tom qab thiab txo qis glycemic inconstancy.
Tshaj li kev tswj glycemic, exenatide acetate muab cov txiaj ntsig ntxiv rau cov tib neeg uas muaj ntshav qab zib hom 2.Nws cuam tshuam rau kev ncua lub plab zom mov tuaj yeem ntxiv rau qhov hnyav los ntawm kev ua kom satiety thiab txo qis caloric nkag. Qhov cuam tshuam qhov hnyav no yog qhov tshwj xeeb tshaj yog rau cov neeg rog rog lossis cov neeg mob loj uas muaj ntshav qab zib hom 2, vim tias qhov hnyav txo tuaj yeem txhim kho kev paub txog insulin ntxiv thiab hauv kev noj qab haus huv hauv metabolic.
Tsis tas li ntawd, exenatide acetate derivation tau tshwm sim los ua kom muaj txiaj ntsig zoo ntawm cov hlab plawv, nrog rau kev txo qis cov mem tes thiab txhim kho lipid profile ntxiv. Cov txiaj ntsig ntawm cov hlab plawv no yog qhov tseem ceeb tshaj plaws uas muab kev twv txiaj ntxiv ntawm cov kab mob plawv cuam tshuam nrog hom 2 mob ntshav qab zib.
Hauv cov ntsiab lus, exenatide acetate derivation tseem yog tus kws kho mob muaj zog hauv kev tswj hwm hom 2 mob ntshav qab zib mellitus. Los ntawm nws cov GLP-1 receptor agonism, nws txhim kho glycemic tswj nrog rau muaj cov txiaj ntsig zoo xws li txo qhov hnyav thiab kev ruaj ntseg ntawm lub plawv. Nrog nws cov txheej txheem ntau yam ntawm kev ua si thiab ua tiav cov txiaj ntsig zoo, exenatide acetate derivation tseem nyob rau hauv kev xav tias yog ib qho tseem ceeb hauv kev txhim kho kev noj qab haus huv thiab kev vam meej ntawm cov tib neeg uas muaj ntshav qab zib hom 2.
Dab tsi yog cov txheej txheem ntawm kev ua ntawm Exenatide Acetate?
exenatide acetate derivation, ib qho tshuaj siv hauv kev kho mob ntshav qab zib hom 2, siv nws cov kev cuam tshuam los ntawm kev ua haujlwm sib txawv, ua rau nws yog ib qho khoom siv tseem ceeb hauv kev kho mob. Ib qho ntawm nws cov tswv yim tseem ceeb rau kev txav mus los tej zaum yog GLP -1 receptor agonist, tiag tiag cuam tshuam qhov kev txiav txim ntawm endogenous GLP-1 (glucagon-zoo li peptide-1).Los ntawm kev khi rau GLP{ {5}} receptors, exenatide acetate stimulates insulin secretion los ntawm pancreatic beta hlwb. Qhov tseem ceeb, qhov kev tso tawm ntawm cov tshuaj insulin no tshwm sim nyob rau hauv txoj kev piam thaj-sab hauv, txhais tau tias nws tau teem tseg thaum cov ntshav qabzib nce siab, tom qab txo qis kev twv txiaj ntawm hypoglycemia.
Tsis tas li ntawd, exenatide acidic corrosive induction pab saib xyuas cov qib qabzib los ntawm kev tso tawm glucagon, ib qho kev sib xyaw uas niaj hnub nce ntshav qabzib. Los ntawm kev cuam tshuam glucagon tso tawm, exenatide acetate derivation pab nrog forestalling exorbitant qabzib tsim los ntawm lub siab, ntxiv rau kev txhim kho glycemic tswj.
Lwm qhov tseem ceeb mechanism ntawmexenatide acetate hmoovyog nws lub peev xwm los ncua lub plab khoob. Los ntawm kev hu rov qab tus nqi ntawm cov zaub mov tawm hauv lub plab thiab nkag mus rau hauv lub plab zom mov me, exenatide acetate derivation pab txo qis qhov nce hauv cov ntshav qabzib tom qab noj mov, raws li kev txo qis postprandial hyperglycemia.
Tsis tas li ntawd, exenatide acetate txhawb kev satiety, lossis kev xav ntawm kev puv, uas tuaj yeem pab cov neeg mob ntshav qab zib hom 2 tswj lawv qhov hnyav. Los ntawm kev hloov pauv kev noj qab haus huv thiab kev noj zaub mov, exenatide acetate tuaj yeem pab txhawb kev ua tiav thiab tswj lub cev hnyav, uas yog qhov tseem ceeb rau kev tswj hwm ntshav qab zib tag nrho thiab txo qhov kev pheej hmoo ntawm cov teeb meem.
Qhov tseem ceeb, exenatide acetate derivation kuj tau tshwm sim los txiav txim siab cuam tshuam rau pancreatic beta-cell muaj peev xwm thiab kev ua siab ntev. Kev tiv thaiv beta-cell muaj peev xwm yog qhov tseem ceeb rau kev ua kom ntev ntev ntawm kev tsim cov tshuaj insulin hauv cov neeg mob ntshav qab zib hom 2, thaum kawg ntxiv rau kev tswj glycemic zoo dua thiab muaj peev xwm ncua kev mob nkeeg.
Hauv cov ntsiab lus,exenatide acetate hmoovderivation's multi-layered Cheebtsam ntawm kev ua, suav nrog GLP-1 receptor agonism, zais glucagon tso tawm, ncua kev ua pa ntawm lub plab, thiab kev nce siab ntawm satiety, ua rau nws yog ib qho kev xaiv tseem ceeb rau kev saib xyuas hom 2 mob ntshav qab zib thiab muaj feem xyuam nrog kev tsis meej pem. Nws lub peev xwm los txhim kho glycemic tswj, txhawb nqa hnyav rau cov thawj coj, thiab tiv thaiv beta-cell muaj peev xwm hais txog nws qhov tseem ceeb hauv kev kho mob ntawm qhov xwm txheej tas li.
Exenatide Acetate pab tswj qhov hnyav hauv cov neeg mob ntshav qab zib li cas?
Qhov hnyav ntawm lub rooj tsavxwm yog ib feem tseem ceeb ntawm kev saib xyuas ntshav qab zib, tshwj xeeb tshaj yog siv rau hauv qhov chaw loj ntawm lub zog rau cov corpulence thiab hom 2 mob ntshav qab zib.Exenatide acetate hmoovmuaj cov txiaj ntsig tseem ceeb hauv qhov no vim nws cuam tshuam rau kev noj qab haus huv tswj thiab satiety. Los ntawm kev ua kom GLP-1 receptors nyob rau hauv lub hauv paus paj hlwb, exenatide acetate pab tswj cov zaub mov noj thiab txo cov calories noj.
Ntxiv mus,exenatide acetate hmoovtau txuam nrog kev poob phaus hauv ntau cov kev tshawb fawb soj ntsuam. Qhov kev txo qhov hnyav no suav nrog rau qhov sib txawv xws li txo qis kev nkag mus rau lub zog, ncua kev tso pa tawm hauv lub plab, thiab siv zog ntxiv. Rau cov neeg mob uas muaj ntshav qab zib hom 2 uas sib ntaus sib tua nrog stoutness lossis rog dhau, exenatide acetic acid derivation tuaj yeem yog tus pab cuam tseem ceeb rau kev hloov pauv lub neej kom ua tiav thiab ua kom lub suab nrov.
3. Dab tsi yog cov txiaj ntsig ntawm cov hlab plawv ntawm Exenatide Acetate?
Yav dhau los nws cov txiaj ntsig rau kev tswj glycemic thiab hnyav cov thawj coj, exenatide acetic acid derivation tau nthuav tawm cov txiaj ntsig tseem ceeb ntawm cov hlab plawv hauv cov neeg mob ntshav qab zib hom 2. Cov kws kho mob ua ntej, piv txwv li, EXSCEL thawj zaug tau pom tias exenatide acetic acid derivation txo qhov kev twv txiaj ntawm cov xwm txheej mob plawv loj (MACE) hauv cov neeg mob uas muaj kev pheej hmoo siab. Cov sijhawm no suav nrog kev tuag ntawm cov hlab plawv, tsis tuag myocardial localized necrosis, thiab mob stroke tsis tuag.
Cov txiaj ntsig ntawm cov hlab plawv ntawm exenatide acetate tau xav tias yog cov khoom siv ntau. Tsis tas li ntawd, nws cov kev ua ntawm vascular kev ua haujlwm thiab endothelial kev noj qab haus huv pab txhawb kev txhim kho cov hlab plawv.
Hauv kev xaus, exenatide acetate yog qhov kev xaiv zoo tshaj plaws rau cov neeg mob ntshav qab zib hom 2, muab cov txiaj ntsig tshaj li kev tswj glycemic.Nws cov haujlwm, suav nrog GLP-1 receptor enactment, kev tshaib kev nqhis, thiab kev ruaj ntseg ntawm lub plawv, ua rau nws lub hauv paus hauv ua tiav kev tswj hwm ntawm ntshav qab zib thiab nws cov entanglements.
Cov ntaub ntawv:
1. Buse JB, et al. Exenatide ib zaug ib lub lim tiam piv rau liraglutide ib hnub ib zaug hauv cov neeg mob ntshav qab zib hom 2 (DURATION-6): ib qho kev tshawb nrhiav randomised, qhib-label. Lancet. 2013; 381 (9861): 117–124.
2. Marso SP, et al. Liraglutide thiab cov txiaj ntsig ntawm cov hlab plawv hauv ntshav qab zib hom 2. N Engl J Med. 2016; 375(4):311–322.
3. Madsbad S. Kev tshuaj xyuas lub taub hau-rau-lub taub hau kev sib piv ntawm glucagon-zoo li peptide-1 receptor agonists. Diabetes Obes Metab. 2016; 18(4): 317–332.
4. Gerstein HC, et al. Dulaglutide thiab cov txiaj ntsig ntawm cov hlab plawv hauv ntshav qab zib hom 2 (REWIND): ob qhov muag tsis pom kev, randomized placebo-controlled sim. Lancet. 2019; 394(10193): 121–130.
5. Pfeffer MA, et al. Lixisenatide nyob rau hauv cov neeg mob uas muaj ntshav qab zib hom 2 thiab mob coronary syndrome. N Engl J Med. 2015; 373(23): 2247–2257.
6. Drucker DJ. Mechanisms ntawm kev nqis tes ua thiab kev kho mob ntawm glucagon-zoo li peptide -1. Cell Metab. 2018; 27(4): 740–756.
7. FDA Kev Tshuaj Xyuas Cov Lus Qhia rau Byetta (exenatide) txhaj.
8. Rosenstock J, et al. Kev ua tau zoo thiab kev nyab xeeb ntawm lixisenatide ib zaug ib hnub piv rau exenatide ob zaug hauv ib hnub hauv hom 2 mob ntshav qab zib mellitus tswj tsis tau zoo ntawm metformin: ib lub lim tiam, randomized, qhib-daim ntawv lo, kev tshawb fawb tswj (GetGoal-X).
9. Baggio LL, Drucker DJ. Biology ntawm incretins: GLP-1 thiab GIP. Gastroenterology. 2007; 132(6): 2131–2157.
10. Patorno E, et al. Cov txiaj ntsig ntawm cov hlab plawv cuam tshuam nrog canagliflozin piv rau lwm cov tshuaj uas tsis yog-gliflozin antidiabetic: cov pejxeem raws li kev tshawb fawb. BMJ. Xyoo 2018; 360: K119.